Canada Approves mRNA Flu and Flu-COVID Vaccines

What do Canada’s new mRNA vaccine authorizations mean?

Moderna announced that Health Canada authorized mFLUSIVA, developed as mRNA-1010, and mCOFLU, developed as mRNA-1083. The first targets seasonal influenza A and B strains represented in the vaccine; the second adds protection against SARS-CoV-2. These are preventive vaccines, rather than treatments for an infection already underway. [Moderna authorization announcement](https://www.pharmaceutical-tech.com/pressreleases/health-canada-authorizes-modernas-mrna-influenza).

A combined vaccine could simplify seasonal vaccination by delivering both components in one injection. However, authorization does not itself establish pharmacy availability, public funding or recommendations for particular patient groups. Moderna said it would work with Canadian health authorities and immunization partners on future availability; its announcement did not provide a firm rollout date. [Moderna authorization announcement](https://www.pharmaceutical-tech.com/pressreleases/health-canada-authorizes-modernas-mrna-influenza).

How effective was the standalone mRNA flu vaccine?

The randomized phase 3 trial, published in the New England Journal of Medicine, included 40,703 vaccinated adults aged 50 or older. Laboratory-confirmed influenza-like illness occurred in 2.0% of evaluable mRNA vaccine recipients and 2.8% of comparator recipients. The reported 26.6% relative efficacy describes the reduction compared with another vaccine, not protection compared with remaining unvaccinated. Using the rounded event rates, the absolute difference was approximately 0.8 percentage points. [Published influenza vaccine trial](https://www.nejm.org/doi/10.1056/NEJMoa2516491).

The comparator matters: this clinical efficacy result does not establish superiority over high-dose or adjuvanted influenza vaccines. Injection-site pain, fatigue, headache and muscle aches were more frequent with mRNA-1010, although most were temporary and mild to moderate. Serious adverse events occurred in both groups. The trial was funded by Blackstone Life Sciences and Moderna, a relevant disclosure when assessing the findings. [Trial results and funding](https://www.nejm.org/doi/10.1056/NEJMoa2516491).

Does the combination vaccine provide better protection than separate shots?

The phase 3 mRNA-1083 trial published in JAMA compared one combined injection with separately administered influenza and COVID-19 vaccines. Participants aged 65 and older received a high-dose influenza comparator; those aged 50–64 received a standard-dose comparator. The combination met prespecified criteria showing that immune responses were not meaningfully worse than the comparators and produced higher responses against several tested targets. [Published combination vaccine trial](https://jamanetwork.com/journals/jama/fullarticle/2833668).

Antibody measurements help predict protection, but they are different from directly counting infections, hospital admissions or deaths. Consequently, stronger antibody responses should not be presented as proof that the combination prevents more severe disease than separate shots. The study supported its immune response and tolerability profile; subsequent effectiveness studies and safety monitoring will help establish performance across seasons and wider patient populations. For patients, convenience is a plausible advantage, while the size of any additional clinical benefit remains uncertain. [Trial interpretation and limitations](https://jamanetwork.com/journals/jama/fullarticle/2833668).